|Mr. Li Chen||Exec. MD, CEO & Exec. Director||575.6k||N/A||1962|
|Mr. Kai Fai Pang||Fin. Mang. & Company Sec.||N/A||N/A||N/A|
|Mr. Yu Zhao||Group HR Director||N/A||N/A||1973|
|Mr. Jianshe Nan||Head of Bus. Devel.||N/A||N/A||1966|
|Mr. Hua Li||Head of Fin. Management Centre||N/A||N/A||1985|
Lansen Pharmaceutical Holdings Limited, an investment holding company, develops, produces, and sells specialty pharmaceuticals for use in the field of rheumatology, dermatology, and other pharmaceuticals in the People's Republic of China and internationally. It operates through Pharmaceuticals, Medical Cosmetics Products, and Healthcare Products segments. The company's specialist medicines comprise Pafulin, which includes total glucosides of white peony capsules; Hepai, a leflunomide tablet; and mycophenolate mofetil dispersible capsules. It also offers Chinese medicine generic drugs; IVD products; health foods; medical cosmetics; and healthcare products, as well as natural plant extracts. The company was founded in 2001 and is headquartered in Ningbo, the People's Republic of China. Lansen Pharmaceutical Holdings Limited is a subsidiary of Cathay International Pharma Manufacture and Distribution (China) Limited.
Lansen Pharmaceutical Holdings Limited’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.